Medicare Reimbursement For Investigative Devices Supported By IoM
This article was originally published in The Gray Sheet
Executive Summary
Medicare should automatically cover the cost of investigative category B medical devices for beneficiaries participating in randomized clinical studies, an Institute of Medicine committee recommends in a report, "Extending Medicare Reimbursement in Clinical Trials," released Dec. 15 at a press briefing in Washington, D.C.
You may also be interested in...
HCFA Support Of CREST Study Could By Aided By White House Directive
President Clinton's June 7 executive memorandum aimed at increasing the participation of Medicare beneficiaries in clinical trials could facilitate federal reimbursement for studies of currently non-covered procedures, such as the CREST carotid stent trial.
HCFA Support Of CREST Study Could By Aided By White House Directive
President Clinton's June 7 executive memorandum aimed at increasing the participation of Medicare beneficiaries in clinical trials could facilitate federal reimbursement for studies of currently non-covered procedures, such as the CREST carotid stent trial.
HCFA Conditional Coverage For Clinical Trials Unlikely In Near-Term
The Health Care Financing Administration will not provide "conditional coverage" under Medicare for the ongoing REMATCH trial evaluating congestive heart failure treatment using Thermo Cardiosystems, Inc.'s HeartMate left ventricular assist device.